Introduction {#s1}
============

Neurotransmitters elicit their effects by activating receptors on the surface of neurons. G protein-coupled receptors (GPCRs) form the largest group of the receptors responsible for the actions of the majority of neurotransmitters and play a critical role in virtually all neuronal functions ([@bib18]; [@bib72]). In a classical model, upon binding to neurotransmitter, GPCRs undergo conformational changes activating heterotrimeric G proteins by promoting GTP binding to Gα subunits and triggering the release of the Gβγ subunits. When dissociated, both Gα and Gβγ subunits modulate the activities of downstream effector molecules that are directly responsible for generating cellular responses ([@bib21]; [@bib48]). However, an emerging alternative model suggests that G protein heterotrimers exist in more stable complexes that rearrange rather than dissociate upon activation and may further form higher order signaling complexes with receptors and effectors ([@bib5]; [@bib15]; [@bib25]; [@bib38]). The assembly of this macromolecular complex may be tightly regulated. Indeed, several chaperone proteins have been described to be required for the biogenesis of the G protein subunits and their complexes ([@bib15]; [@bib54]; [@bib73]).

One of the central and best studied G protein effectors is adenylyl cyclase (AC), an enzyme that catalyzes the synthesis of the second messenger cyclic adenosine monophosphate (cAMP) ([@bib68]). Numerous isoforms of AC are differentially modulated by both Gβγ and various Gα-GTP subunits and play critical roles in a variety of fundamental neuronal processes ([@bib58]; [@bib66]). GPCR signaling to AC performs a particularly important function in the striatum, the input structure of the basal ganglia circuit essential for initiating and maintaining movement, mood control, and reward valuation ([@bib23]; [@bib35]). Imbalance in cAMP homeostasis in this region has been associated with drug addiction, bipolar disorder, schizophrenia and a variety of movement disorders ([@bib4]; [@bib22]; [@bib50]; [@bib74]). Striatal neurons receive diverse inputs that converge on AC5, the major AC isoform in the region, accounting for \~ 80% of cAMP generation ([@bib40]). Coupling of key neurotransmitter receptors, such as dopamine D1 (D1R) and adenosine A2A (A2AR) to increase cAMP production in these neurons, is mediated to a large extent by a unique heterotrimer composed of the stimulatory α subunit Gα~olf~ complexed with Gβ~2~ and Gγ~7~ subunits ([@bib26]). Indeed, deletion of Gα~olf~, Gγ~7~ or AC5 in mice severely diminishes cAMP production in response to D1R and A2AR activation, which is paralleled by muted behavioral responses to psychostimulants and antipsychotics that act on these receptors as well as by profound motor deficits ([@bib11]; [@bib29]; [@bib40]; [@bib60]; [@bib65]). Recently, mutations in Gα~olf~ and AC5 have been shown to cause primary dystonia in humans ([@bib7]; [@bib16]; [@bib36]), further supporting the key contribution of G~olf-~AC5 signaling axis to pathophysiology of movement disorders. These observations argue for the lack of functional compensation from other AC isoforms and heterotrimeric G proteins in transducing the signal. However, the functional significance of striatal-specific composition of these specific signaling elements is not well understood.

Functionally, Gα~olf~ is similar to another stimulatory G protein Gα~s~, but Gα~olf~ has lower efficiency of both receptor coupling and AC5 stimulation when tested in in vitro biochemical assays ([@bib9]; [@bib31]). AC5 displays dual regulation by G protein subunits in which Gβγ acts to facilitate its activation by Gα~s~ ([@bib19]). In vitro biochemical studies show that AC5 is capable of binding Gα~s~ and Gβγ simultaneously, suggesting that it can scaffold the stimulatory G protein heterotrimers ([@bib58]). In fact, growing evidence suggests that in vivo G~olf~-AC5 may exist in a signaling complex ([@bib26]). In mice, AC5 elimination leads to a reduction in expression levels of Gα~olf~ in the striatum ([@bib30]). Similarly, knockout of Gγ7 reduces the expression of Gα~olf~ and Gβ~2~ ([@bib60]; [@bib65]). However, interactions involving elements of the complex in the striatum, their reciprocal relationship, mechanisms of complex assembly as well as implications for the cAMP signaling and behavior are not understood.

Here we report that in the striatum, AC5 forms a stable macromolecular complex with heterotrimeric Golf proteins and this pre-assembly is essential for the stability of AC5 and its ability to produce cAMP. We identified that the Gβ chaperone phosducin-like protein 1 (PhLP1) plays a key role in the assembly of this signaling complex in striatal neurons. Elimination of PhLP1 in striatal neurons affects assembly and stability of the complex and causes selective impairment in sensorimotor behavior and motor skill learning, preferentially affecting signaling in the striatopallidal medium spiny neurons.

Results {#s2}
=======

Stability of AC5 in the stratum depends on its complex formation with the Golf heterotrimer {#s2-1}
-------------------------------------------------------------------------------------------

To begin testing the idea that AC5 may exist in a stable complex with the Golf heterotrimer in vivo, we first analyzed their binding by co-immunoprecipitaiton assays. AC5 was effectively and specifically pulled down together with both Gαolf and, to a lesser extent, Gβ~2~ from mouse striatal lysates, indicating that in striatal neurons Golf subunits form stable complexes with AC5 in their ground state in the absence of receptor stimulation ([Figure 1A](#fig1){ref-type="fig"}). Next, we analyzed the relationship between AC5 and Golf by examining the co-dependence of their expression using mouse knockout models. Elimination of AC5 in mice (*Adcy5*^-/-^) dramatically reduced the expression of Gαolf but had no appreciable effect on Gβ2 expression, suggesting that AC5 contributes to the stability of Gαolf but not the stability of the Gβ~2~γ~7~ complex ([Figure 1B](#fig1){ref-type="fig"}). We further used *Adcy5*^-/-^ striatal tissues in the immunoprecipitation experiments and found that antibodies against AC5 failed to pull-down G~olf~ subunits from striatal lysates lacking AC5, confirming the specificity of G~olf~ association with AC5 ([Figure 1C](#fig1){ref-type="fig"}). In contrast, disruption of Gβ~2~γ~7~ by eliminating Gγ~7~ in *Gng7*^-/-^ knockout led to a marked down-regulation of both AC5 and Gαolf expression ([Figure 1D](#fig1){ref-type="fig"}). The consequences of Gα~olf~ disruption were evaluated in heterozygous mice (*Gnal*^+/-^) with severely diminished Gα~olf~ expression because complete ablation of Gαolf leads to increased perinatal lethality ([@bib3]). In these animals, the levels of both AC5 and Gβ~2~ were substantially reduced ([Figure 1E](#fig1){ref-type="fig"}). Therefore, in mouse striatum co-dependence of the complex components appears to be unidirectional: destabilization of either the Gα or Gβγ subunits of the Golf heterotrimer compromised AC5 stability, while only Gα but not Gβγ was affected by the loss of AC5.10.7554/eLife.10451.003Figure 1.Co-dependence of heterotrimeric G~olf~ subunits and AC5 in complex formation and expression.(**A**) Immunoprecipitation of AC5 complexes from striatal lysates of wild type mice. Specific anti-AC5 antibodies but not non-immune IgGs pull down Gα~olf~β~2~γ~7~ subunits from native striatal tissues. (**B**) Significant reduction of Gα~olf~ expression in striatum tissue from mice lacking AC5. Total striatal lysates were analyzed by immunoblotting using indicated antibodies and quantified by densitometry. \*\*\*p\<0.001, Student's t-test, n = 3 mice. (**C**) Immunoprecipitation of AC5 from wild type (+/+) and Adcy5^-/-^ tissues confirms specificity of AC5-G~olf~ binding. Same anti-AC5 antibodies were used in both immunoprecipitaiton experiments and samples were processed in parallel. (**D**) Significant reduction of AC5 and Gα~olf~ expression in striatal tissues from mice lacking Gγ~7~. Total striatal lysates from wild type and *Gng7*^-/-^ mice were analyzed by immunoblotting with indicated antibodies and quantified by densitometry. \*p\<0.05, \*\*p\<0.01, Student's t-test, n = 3 mice. (**E**) Significant reduction of AC5 and Gβ~2~ expression in striatal tissues from mice with reduced expression of Gα~olf~. Total striatal lysates from wild type and *Gnal*^+/-^ mice were analyzed by immunoblotting with indicated antibodies and quantified by densitometry. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, Student's t-test, n = 3 mice. (**F**) Mutual stabilization of AC5 and Gα~olf~ upon co-transfection in HEK293 cells. Equal amounts of cDNAs were transfected into cells as described in the Methods section and protein expression was assessed by immunoblotting with specific antibodies (**G**) Lack of co-stabilization between AC5 and Gβ~2~γ~7~ subunits in co-transfected HEK293 cells. Indicated constructs were transfected into cells and changes in protein expression were monitored by immunoblotting with specific antibodies. (**H**) Mutual stabilization of Gα~olf~ subunits with Gβ~2~γ~7~ subunits in co-transfected HEK293 cells. The experiment was conducted as described for panel G.**DOI:** [http://dx.doi.org/10.7554/eLife.10451.003](10.7554/eLife.10451.003)

We further examined the relationship between Golf subunits and AC5 in transfected HEK293 cells. Consistent with the in vivo data, co-expression with Gα~olf~ dramatically increased levels of AC5, and vice versa, the introduction of AC5 enhanced the expression of Gα~olf~ ([Figure 1F](#fig1){ref-type="fig"}). In contrast, no significant changes in AC5 or Gβ~2~γ~7~ levels were observed upon their co-expression ([Figure 1G](#fig1){ref-type="fig"}). We further observed co-dependence between Gα~olf~ and Gβ~2~γ~7~ subunits in which co-expression with Gα~olf~ increased the levels of Gβ~2~γ~7~ and co-expression of Gβ~2~γ~7~ enhanced levels Gα~olf~ ([Figure 1H](#fig1){ref-type="fig"}). Collectively, these data strongly support the existence of a complex between AC5 and the Gα~olf~β~2~γ~7~ heterotrimer and indicate that the association between components of this complex is required for its stability.

PhLP1 facilitates the Gα~olf~β~2~γ~7~ expression, assembly and functional activity. {#s2-2}
-----------------------------------------------------------------------------------

In search of factors that may regulate the assembly of G~olf~-AC5 complex, our attention was drawn to phosducin like protein 1 (PhLP1), which has been described to serve as a co-factor for the assembly of signaling complexes containing β subunits of heterotrimeric G proteins ([@bib73]). In HEK293 cells, co-transfection with PhLP1 significantly increased the expression of all three G~olf~ subunits ([Figure 2A](#fig2){ref-type="fig"}). In contrast, a dominant negative construct of PhLP1 (ΔNT-PhLP1), lacking the first 75 amino acids critical for its interaction with Gβ ([@bib44]) had no effect on the expression G~olf~ subunits ([Figure 2A](#fig2){ref-type="fig"}). Consistent with the described impact of PhLP1 on Gβγ complexes ([@bib44]), co-expression with full-length PhLP1 resulted in a significant increase in the formation of the Gβ~2~γ~7~ complexes as evidenced by the fluorescence complementation assay with the split-Venus system ([Figure 2B](#fig2){ref-type="fig"}). In contrast, ΔNT-PhLP1 exerted the opposite effect and inhibited Gβ~2~γ~7~ assembly ([Figure 2B](#fig2){ref-type="fig"}). To examine the functional effects of PhLP1 in a context of the entire Golf heterotrimer, we tested the ability of Gβ~2~γ~7~ and Gα~olf~ subunits to undergo a cycle of dissociation/re-association in response to changes in the D1R activity. We used a cell-based Bioluminescence Energy Transfer (BRET) assay to monitor the release of the Gβ~2~γ~7~ dimer in the presence of Gα~olf~ ([Figure 2C](#fig2){ref-type="fig"}). In this assay, stimulation of D1R by dopamine results in the activation of Gα~olf~, releasing Venus-tagged Gβ~2~γ~7~ to interact with the NanoLuc-tagged reporter, an event detected by changes in the BRET signal. Conversely, application of an antagonist SCH39166 facilitates complex re-association and quenching of the BRET response ([Figure 2D](#fig2){ref-type="fig"}). Reversing the sequence of ligand addition abolishes the response indicating that changes in the BRET signal are associated with the activation of the D1R receptors ([Figure 2D](#fig2){ref-type="fig"}). Furthermore, omitting D1R or G~olf~ from the transfection also dramatically suppressed the signal indicating that the signal is specifically driven by the D1R-mediated activation of the G~olf~ ([Figure 2E](#fig2){ref-type="fig"}). Using this assay we found that PhLP1 coexpression significantly increased dopamine-induced activation of Gα~olf~-Gβ~2~γ~7~ heterotrimer ([Figure 2F,G](#fig2){ref-type="fig"}). In contrast, expression of the dominant negative ΔNT-PhLP1 significantly attenuated the BRET response ([Figure 2F,G](#fig2){ref-type="fig"}). These observations suggest that PhLP1 facilitates functional coupling of Gα~olf~Gβ~2~γ~7~ to D1 receptors, likely owning to its ability to promote the assembly of Gβ~2~γ~7~ complexes.10.7554/eLife.10451.004Figure 2.PhLP1 facilitates functional assembly of Gα~olf~β~2~γ~7~ complex.(**A**) *Left,* Full length of PhLP1 but not its N terminally truncated mutant ΔNT-PhLP1 increases the expression level of Gα~olf~β~2~γ~7~ subunits upon overexpression in HEK293 cells. *Right*, quantification of immunoblot data from 3 independent experiments. Data were normalized to the individual protein expression in the control group without PhLP1 transfection. Data were analyzed by One-Way ANOVA (Gα~olf~ F\[2, 9\] = 8.731, p = 0.008; Gβ~2~ F\[2, 9\] = 6.688, p = 0.017; Gγ~7~ F\[2, 9\] = 11.107, p = 0.004). \*p\<0.01 compared to the control group post hoc Tukey's test. (**B**) Full length PhLP1 facilitates, while ΔNT-PhLP1 inhibits Gβ~2~γ~7~ assembly. Venus fluorescence intensity was used as a readout of Gβ~2~γ~7~ complex assembly in a complementation experiment in transfected HEK293 cells. Data were analyzed by One-Way ANOVA (F\[2, 15\] = 2719.521, p\<0.001). \*\*p\<0.01, \*\*\*p\<0.001 compared with the control group, post hoc Tukey's test. (**C**) Schematic diagram of BRET sensor strategy for examining the dissociation and reassociation of Gα~olf~ and Gβ~2~γ~7~ subunits upon D1Rs activation and inactivation. (**D**) Representative BRET response traces. Cells transfected with D1R and G~olf~ were stimulated by 100 μM dopamine followed by 100 μM SCH39166 (black) or by 100 μM SCH39166 followed by 100 μM dopamine (red). First and second ligands were applied at 5 and 40 s, respectively. (**E**) Control experiments examining the requirement of both Golf and D1R to transduce the signal. Cells were transfected with the three different conditions, Golf only, D1R only, or D1R plus G~olf~. Each bar represents the mean of 6 replicates. (**F**) Representative BRET signal traces in response to D1 receptor activation with dopamine (100 μM). (**G**) Comparison of maximal BRET ratios. Data were analyzed by One-Way ANOVA (F\[2, 9\] = 706.655, p\<0.001). \*\*p\<0.01 compared with the control group, post hoc Tukey's test.**DOI:** [http://dx.doi.org/10.7554/eLife.10451.004](10.7554/eLife.10451.004)

PhLP1 increases stimulatory regulation of AC5 {#s2-3}
---------------------------------------------

The observations that AC5 expression is sensitive to changes in the levels of the Golf and that PhLP1 increases the expression of G~olf~ subunits suggested that PhLP1 might modulate AC5 activity. We tested this possibility by measuring the effect of PhLP1 co-expression on AC5 expression. PhLP1 co-expression resulted in a significant increase (\~1.7 fold) in AC5 expression ([Figure 3A](#fig3){ref-type="fig"}). This effect was paralleled by elevation of the basal cAMP levels (\~4 fold) in the cells expressing AC5 ([Figure 3B](#fig3){ref-type="fig"}). In addition, AC5-containing cells showed enhanced cAMP generation in response to both the direct AC activator forskolin (\~4 fold increase) and the β2-adrenergic agonist isoproterenol (\~1.5 fold increase) when PhLP1 was overexpressed ([Figure 3B](#fig3){ref-type="fig"}). These effects were AC5-dependent as no stimulatory effect on cAMP generation was observed in the absence of AC5 ([Figure 3C](#fig3){ref-type="fig"}). Interestingly, while the increase in GPCR-driven cAMP production (likely through Gα~s~) in the presence of PhLP1 closely matched the increase in the total AC5 levels, the effect of PhLP1 on both basal and forskolin-induced cAMP production was much larger. These observations suggest that PhLP1 may exert functional effects on cAMP production that are independent from increasing AC expression.10.7554/eLife.10451.005Figure 3.PhLP1 augments expression and activity of AC5.(**A**) Co-expression of PhLP1 significantly increases AC5 expression in HEK293 cells. \*\*p\<0.01 Students' t-test, n = 3. (**B**) PhLP1 enhances cAMP levels under basal condition, or in response to stimulation with forskolin (FSK, 1 μM, 5 min) or isoproterenol (ISO, 1 μM, 5 min) in AC5 expressing HEK293 cells. \*\*p\<0.01 Student's t-test, n = 3. (**C**) PhLP1 has no effect on cAMP generation in HEK293 cells without AC5 overexpression. n = 3 (**D**) Effects of purified recombinant full length PhLP1 and ΔNT-PhLP1 on adenylyl cyclase activity in striatal membranes. Assays were performed in the absence of GTP. Striatal membranes were pre-incubated with 0.5 μM of purified proteins at 4°C for 20 min and then subjected to adenylyl cyclase activity assay. Data were analyzed by One-Way ANOVA (F\[2, 9\] = 35.477, p\<0.001). \*\*p\<0.01, post hoc Tukey's test. n = 3 (**E**) Purified recombinant PhLP1 enhances forskolin-stimulated adenylyl cyclase activity in striatal membranes. Membranes were pre-incubated with 0.5 μM of purified proteins at 4°C for 20 min. Membranes were then stimulated with 1 μM forskolin or 80 nM Gα~s~-GTPγS. Data were analyzed by One-Way ANOVA (F(4, 15) = 52.291, p\<0.001).\*\*\*p\<0.001, post hoc Tukey's test. n = 3 (**F**) Effect of purified recombinant PhLP1 on the dose response of forskolin-mediated activation of adenylyl cyclase in striatal membranes. The EC~50~ for forskolin was 32.5 ± 2.7 μM in the control reaction and 8.9 ± 1.6 μM in PhLP1-treated reaction. \*\*p\<0.01 Student's t-test, n = 3. (**G**) Effect of purified recombinant PhLP1 on the dose response of Gα~s~-GTPγS-mediated activation of adenylyl cyclase in striatal membranes. The EC~50~ for Gα~s~-GTPγS was 16.2 ± 4.7 nM in the control reaction and 22.3 ± 5.7 nM in PhLP1-treated reaction (n = 3 reactions).**DOI:** [http://dx.doi.org/10.7554/eLife.10451.005](10.7554/eLife.10451.005)

To gain mechanistic insight into the nature of this regulation in a more physiological setting, we performed adenylyl cyclase activity assays using membrane isolated from mouse striatum. Remarkably, purified recombinant full-length PhLP1 significantly enhanced basal AC activity ([Figure 3D](#fig3){ref-type="fig"}). This effect was not observed with ΔNT-PhLP1, suggesting that the effect likely involves an ability of PhLP1 to bind Gβγ. The reaction buffer in these assays did not contain GTP, therefore the effect of PhLP1 was unlikely to result from the classical activation of Gα. Given that in the striatal membranes AC5 forms a complex with Gα~olf~Gβ~2~γ~7~ we hypothesized that PhLP1 may cause activation by scavenging Gβγ and releasing Gα~olf~, making it available for the activation of AC5, as even GDP-bound free Gα subunits are capable of regulating AC ([@bib67]). To test this notion, we compared the ability of forskolin and Gα~s~-GTP to regulate AC activity in the striatal membranes in the absence or presence of PhLP1. Gα~s~ is known to synergize with forskolin increasing its ability to regulate cyclase activity by promoting binding of forskolin to a high affinity site ([@bib13]). Consistent with our model, PhLP1 significantly enhanced forskolin-stimulated AC activity in striatal membranes and produced an approximately three-fold reduction in EC~50~ for forskolin ([Figure 3E and F](#fig3){ref-type="fig"}). In contrast, PhLP1 failed to exert an effect on AC activated by adding exogenous Gα~s~-GTPγS ([Figure 3E and G](#fig3){ref-type="fig"}) supporting the idea that PhLP1 activates AC5 through a Gα-dependent mechanism. In this case, added Gα~s~-GTPγS likely out competed endogenous Gα~olf~-GDP activating AC5 after being released by PhLP1. Thus, PhLP1 appears to regulate AC5 activity by a dual mechanism. On the one hand it enhances the expression of the AC5 by facilitating its complex formation with G~olf~. On the other, it may act in promoting the receptor-independent release of Gαolf that stimulates AC5 activity.

Elimination of PhLP1 does not impact survival and connectivity of striatal neurons {#s2-4}
----------------------------------------------------------------------------------

We next sought to examine the effect of PhLP1 on striatal signaling and physiology in vivo. In agreement with previous reports ([@bib63]), we found PhLP1 protein to be abundantly expressed in the mouse striatum by immunoblotting ([Figure 4A](#fig4){ref-type="fig"}). To study the role of PhLP1 in the striatum, we ablated its expression selectively in the striatum by crossing the conditional PhLP1 mouse strain (*Pdcl^flx/flx^*) with the striatal driver mouse line *Rgs9-Cre*, generating a conditional, striatal-specific elimination of PhLP1 (*Pdcl* cKO) mouse ([Figure 4B](#fig4){ref-type="fig"}). In this line recombination likely occurs postnatally, as expression of the *Rgs9* gene is induced around P3 to P6 ([@bib1]). We began our analysis by assessing possible anatomical changes because previous studies indicated that elimination of PhLP1 may lead to neuronal degeneration ([@bib37]). Overall, striatal morphology of *Pdcl* cKO mice looked normal with no signs of degeneration at least until 3--4 months of age ([Figure 4C](#fig4){ref-type="fig"}). Morphometric analysis revealed a decrease in the total volume of striatal tissue in *Pdcl* cKO mice ([Figure 4D](#fig4){ref-type="fig"}). Counting the number of neurons (diameter \> 5 μm) in the striatum tissue using Nissl staining revealed a significantly greater number of neurons in the *Pdcl* cKO mice. A greater number of cells together with a smaller volume that they occupy indicate that the sizes of individual striatal neurons are likely smaller. These changes are consistent with retarded maturation of neurons, a process controlled by the cAMP signaling ([@bib17]; [@bib47]). We next analyzed projections of striatal medium spiny neurons to the target regions Globus Pallidus (GPe) and Substantia Nigra (SNr), revealed by immunostaining for enkephalin and substance P, respectively. Quantification of fluorescence intensity revealed no difference in the intensities of the signals for these markers, which were found in appropriate target areas ([Figure 4E](#fig4){ref-type="fig"}). In summary, these data indicate that loss of PhLP1 in the striatum does not lead to neuronal degeneration, but rather promotes neuronal survival while inhibiting their growth.10.7554/eLife.10451.006Figure 4.Elimination of PhLP1 does not impact survival and connectivity of striatal neurons.(**A**) PhLP1 expression in different brain regions from adult mice as determined by immunoblot analysis. (**B**) Generation of PhLP1 conditional knockout out. *Pdcl^flx/flx^*mice were crossed with *Rgs9-Cre* mice to generate striatal specific PhLP1 conditional knockout (*Pdcl* cKO) mice (**C**) Representative images of Nissl-stained coronal brain sections from adult control and *Pdcl* cKO mice. Stm, striatum. (Scale bar, 1 mm). (**D**) *Left*: Striatal volume of adult *Pdcl* cKO mice was reduced by 30% as compared with control mice (n = 4 mice each). Error bars represent SEM. Student's t test: \*\*p\<0.01. *Right*: Counts of striatal neurons in *Pdcl* cKO and control mice obtained from Nissl-stained sections. The striatal neuron counts were increased by 43% compared with control mice (n = 4 mice each). Error bars represent SEM. Student's t test: \*p\<0.05. (**E**) *Left*: Representative images of anti-enkephalin and anti-substance-P stained brain sections. GPe, external globus pallidus. SNr, substantia nigra pars reticulate. (Scale bar, 2 mm.) *Right*: Quantification of immunofluorescent signal for enkephalin and substance-P. Mean intensity of signals from both antibodies showed no significant difference between control and *Pdcl* cKO mice. Error bars represent SEM.**DOI:** [http://dx.doi.org/10.7554/eLife.10451.006](10.7554/eLife.10451.006)

Elimination of PhLP1 in striatal neurons destabilizes AC5-G~olf~ complexes and leads to cAMP signaling deficits {#s2-5}
---------------------------------------------------------------------------------------------------------------

Our studies in vitro and in heterologous expression system indicate a role for PhLP1 in the assembly of the Gα~olf~Gβ~2~γ~7~ complex. Previous in vivo studies also demonstrated that PhLP1 is required for the assembly of Gβ~1~ with Gαt~1~ and Gβ~3~ with Gα~t2~ as well as Gβ~5~ complexes with RGS9-1 ([@bib37], [@bib70]). Therefore, we proceeded to investigate the consequences of PhLP1 ablation on the expression of various subunits of heterotrimeric G proteins, RGS proteins and AC5 in the striatum ([Figure 5A](#fig5){ref-type="fig"}). Immunoblotting shows that the levels of PhLP1 protein were reduced by \~60% in *Pdcl* cKO striatum. Consistent with the results in transfected cells, we found that the levels of Gα~olf~, Gβ~2~ and AC5 were severely reduced in *Pdcl* cKO as well. Deletion of PhLP1 also had a detrimental effect on the expression of Gβ~5~ and RGS9-2, as may have been expected from the studies on the rod and cone photoreceptors ([@bib37]; [@bib70]). Interestingly, the effect was clearly selective as deletion of PhLP1 did not affect the expression of Gβ~1~ and Gα subunits possibly associated with it: Gα~o~, Gα~i~, Gα~q~ ([Figure 5B](#fig5){ref-type="fig"}). Furthermore, the levels of another Gβ~5~ associated protein, RGS7 were also unaffected. Analysis of the mRNA levels for corresponding down-regulated proteins showed no changes in the transcript levels, suggesting that PhLP1 likely contributes to protein stability rather than affects the expression through a transcriptional mechanism ([Figure 5C](#fig5){ref-type="fig"}). Therefore, it appears that PhLP1 selectively affects biosynthesis and/or assembly of the AC5 signaling complex that in addition to Gα~olf~Gβ~2~γ~7~ also contains RGS9-2/Gβ~5~ ([@bib75]).10.7554/eLife.10451.007Figure 5.Elimination of PhLP1 in striatal neurons significantly impairs expression and function of AC5-Golf complex.(**A**) Representative immunoblot data of AC5, different G protein subunits and RGS proteins in stratal tissues from adult control or *Pdcl* cKO mice. (**B**) Quantification of protein levels. Data were normalized to the percentage of protein level in control mice. \*\*p\<0.01, \*\*\*p\<0.001, Student's t-test, n = 3 mice. (**C**) mRNA quantification in striatum tissue from control and *Pdcl* cKO mice. Data were normalized to the percentage of mRNA level in control mice. (**D**), Basal cAMP level was reduced in the striatum tissue of *Pdcl* cKO mice. \*\*\*p\<0.001, Students' t-test, n = 3 mice. (**E**) Striatal membrane adenylyl cyclase activity is reduced in *Pdcl* cKO mice. Adenylyl cyclase activity was measured either under basal conditions (without stimulation), or in the presence of forskolin (FSK, 1 μM), D1R specific agonist SKF38391 (SKF, 10 μM) or A2AR agonist CGS21680 (CGS, 10 μM). \*p\<0.05, \*\*p\<0.01, Student's t-test, n = 3 reactions.**DOI:** [http://dx.doi.org/10.7554/eLife.10451.007](10.7554/eLife.10451.007)

In agreement with the changes in protein levels, we found marked deficits in cAMP signaling. Basal cAMP levels were substantially lower in the striatum tissues from *Pdcl* cKO mice as compared to their control littermates ([Figure 5D](#fig5){ref-type="fig"}). Adenylyl cyclase activity measured with membranes isolated from the striatum was also lower upon the deletion of PhLP1 under both basal and forskolin-stimulated conditions ([Figure 5E](#fig5){ref-type="fig"}). Finally, the efficiency of D1R and A2AR coupling to cAMP production was lower in *Pdcl* cKO striatal membrane ([Figure 5E](#fig5){ref-type="fig"}). Together, these data indicate that in the striatum PhLP1 is necessary for high-level expression of the AC5 complex components and its functional activity.

Elimination of PhLP1 in striatal neurons results in motor deficits and impaired psychomotor responses to drugs {#s2-6}
--------------------------------------------------------------------------------------------------------------

To better understand the relevance of the observed molecular changes to normal physiology and pathology, we analyzed the behavioral consequences of eliminating PhLP1 in the striatum. We started by assessing the performance of *Pdcl* cKO mice in a battery of striatum-dependent tasks comparing their behavior to control littermates. In the open field test, *Pdcl* cKO mice exhibited normal habituation to a novel environment ([Figure 6A](#fig6){ref-type="fig"}) and had unaltered levels of basal locomotor activity as evidenced by both total distance traveled during the task ([Figure 6B](#fig6){ref-type="fig"}) and average locomotion velocity ([Figure 6C](#fig6){ref-type="fig"}). The *Pdcl* cKO mice also had normal thigmotaxis, stereotypy, pre-pulse inhibition and showed no signs of abnormal involuntary movements or clasping behavior typically associated with gross striatal dysfunction (data not shown).10.7554/eLife.10451.008Figure 6.Behavioral consequences of PhLP1 elimination in striatal neurons.(**A**) *Pdcl* cKO mice display normal basal locomotion and habituation to a novel environment. (**B**) Total distance traveled in 2 hr in the open field chamber. (**C**) Average velocity in the open field chamber. (**D**) *Pdcl* cKO mice exhibit severe deficits in motor learning behavior in rotarod test. There were statistically significant differences between genotype as determined by Two-way ANOVA (F\[1, 153\] = 63.518, p\<0.001). \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, post hoc Tukey's test, n = 9 and 10 for control mice and *Pdcl* cKO mice, respectively. (**E**) Increased grip strength of the forelimbs in *Pdcl* cKO mice. \*p\<0.05, Student's t-test, n = 8 mice for each genotype. (**F**) Increased acoustic startle response of *Pdcl* cKO as measured by Vmax in response to 120 dB white noise bursts. (**G**) Normal locomotor response to D1R agonist SKF 38,393 (SKF, 50 mg/kg, i.p.) in *Pdcl* cKOcompared to control mice. Mice were injected with vehicle or SKF 38,393 (SKF, 50 mg/kg, i.p.) and immediately put in open field chambers. The locomotion was recorded for 1 hr. Data were analyzed by Two-way ANOVA (treatment F\[1, 28\]=96.068, p\<0.001, genotype F\[1, 28\] = 2.679, p = 0.113). \*p\<0.01 post hoc Tukey's test compared to the vehicle control of the same genotype. n=8 mice per each genotype. (**H**) Blunted response to A2AR antagonist SCH58261 (SCH, 3 mg/kg, i.p.) treatment. Data were analyzed by Two-way ANOVA (treatment F(1, 28) = 42.819, p\<0.001, genotype F(1, 28) = 20.181, p\<0.001). \*p\<0.01 post hoc Tukey's test compared to the vehicle control of the same genotype, \#p\<0.05 post hoc Tukey's test in comparison between genotypes in response to SCH 58261. n = 8 mice per each genotype. (**I**) Reduced catalepsy in response to D2R antagonist haloperidol (2 mg/kg, i.p.) in *Pdcl* cKO mice. Catalepsy was measured in the bar test 1 hr after haloperidol (2 mg/kg, i.p.) administration. \*p\<0.05, Student's t-test. n = 8 mice per each genotype.**DOI:** [http://dx.doi.org/10.7554/eLife.10451.008](10.7554/eLife.10451.008)

We next tested animal motor behavior. In the accelerating rotarod task, mice of both genotypes that were naïve to the procedure performed equally during initial trial, indicating their normal motor coordination ([Figure 6D](#fig6){ref-type="fig"}). However, the behavior of *Pdcl* cKO mice was dramatically different when multiple trials were conducted. While the performance of control littermates improved with each subsequent trial, *Pdcl* cKO mice performed at the same level during all trial sessions ([Figure 6D](#fig6){ref-type="fig"}). These data indicate that knockout of *Pdcl* in the striatum completely abolishes motor learning in mice. *Pdcl* cKO mice also showed enhanced forelimb grips strength ([Figure 6E](#fig6){ref-type="fig"}) and augmented response to acoustic startle ([Figure 6F](#fig6){ref-type="fig"}), suggesting further deficits in processing sensorimotor stimuli.

To dissect the influence of PhLP1 on receptor-mediated neurotransmission, we performed pharmacological studies at the behavioral level. Injection of mice with the D1R selective agonist SKF38393 that activates striatal neurons of the direct pathway caused equal psychomotor activation in *Pdcl* cKO mice and their wild-type littermates ([Figure 6G](#fig6){ref-type="fig"}). In contrast, administration of A2AR antagonist SCH58261, that inhibits striatal neurons of the indirect pathway, had no effect on the behavior of *Pdcl* cKO mice while significantly increasing locomotor activity of wild-type littermates ([Figure 6H](#fig6){ref-type="fig"}). Conversely, the D2R antagonist haloperidol, that activates striatopallidal (indirect) pathway, induced catalepsy to a significantly greater extent in control littermates than in *Pdcl* cKO mice ([Figure 6I](#fig6){ref-type="fig"}). In summary, the behavioral data suggest normal baseline behavior of *Pdcl* cKO mice with selective deficits in the striatal-mediated motor learning and sensorimotor coordination, preferentially affecting the function of the striatopallidal pathway.

Discussion {#s3}
==========

Pre-assembly of stable signaling complexes between heterotrimeric Gα~olf~β~2~γ~7~ and AC5 {#s3-1}
-----------------------------------------------------------------------------------------

In this study we demonstrate that AC5, the key cAMP-producing enzyme in the striatum, forms stable complexes with its regulatory G protein species Gα~olf~β~2~γ~7 ~in vivo. We find that this interaction occurs at the basal state and can be detected without agonist application, which is typically required to promote dissociation of heterotrimers into Gα-GTP and Gβγ subunits making them competent for binding to effectors. We further demonstrate that binding to Gα~olf~β~2~γ~7~ complex is required for the proteolytic stabilization of AC5 that results in its high expression level in the striatum. In the course of this study, we further confirmed previously reported interdependence among subunits of the G~olf~ heterotrimer in which interactions between Gα~olf~ and Gβ~2~γ~7~ are required for mutual proteolytic stabilization of the complex ([@bib30]; [@bib64]; [@bib65]). These observations are similar to noted interdependence of Gα~t1~β~1~γ~1~ and Gα~o~β~3~γ~13~ subunits observed in rod photoreceptors ([@bib37]) and ON-bipolar cells ([@bib14]) of the retina, respectively, and likely reflect a general principle in setting subunit stoichiometry in G protein heterotrimeric complexes. While there are several examples for the association of both Gα and Gβγ subunits with effector molecule, e.g. PLCβ, GIRK channels, AC isoforms ([@bib34]; [@bib45]; [@bib66]), to the best of our knowledge this study is the first to document a case in which stable association with all subunits of G protein heterotrimer is required for the stability of an effector. Taken together with biochemical studies showing that AC5 is capable of scaffolding inactive G protein heterotrimers ([@bib58]), our results suggest that in striatal neurons heterotrimeric G~olf~-AC5 is assembled in a pre-coupled 'signalosome' in which subunits rearrange rather than physically dissociate upon GPCR activation.

Role of PhLP1 in G~olf-~AC5 complex assembly {#s3-2}
--------------------------------------------

We report that the chaperone protein PhLP1 plays a critical role in the assembly of the Golf-AC5 complex in striatal neurons. Previous studies have demonstrated the role of PhLP1 in the assembly of the complexes involving Gβ subunits of heterotrimeric G proteins. It is thought to function as a co-chaperone with the cytosolic chaperonin complex (CCT), assisting in retrieval of the Gβ subunits emerging from the CCT and presenting them for the association with the Gg subunits ([@bib73]). In addition to assisting folding of conventional Gβγ complexes, PhLP1 chaperones the formation of the structurally similar complexes involving the atypical Gβ~5~ subunits and the Gγ-like domains in RGS proteins ([@bib28]). Consistent with this model, deletion of PhLP1 in photoreceptors disrupts the formation of Gβ~1~γ~1~ (in rods), Gβ~3~γ~8~ (in cones) and Gβ~5L~/RGS9-1 complexes (in both rods and cones), dramatically decreasing their expression ([@bib37]; [@bib70]). Similarly, overexpression of the dominant negative mutant of PhLP1 deficient in Gβ binding in rods down-regulates the expression of the Gβ~1~γ~1~ and Gβ~5L~/RGS9-1 complexes ([@bib55]). Interestingly, loss of PhLP1 function also results in a dramatic decrease in the expression of Gα~t1~ and Gα~t2~ subunits in rods and cones, respectively ([@bib37]; [@bib70]). Given that stability of these Gα subunits depends on their complex formation with Gbg ([@bib33]; [@bib43]; [@bib51]), the role of PhLP1 in stabilizing Gα~t1~ and Gα~t2~ is likely indirect and stems from its effects on Gβγ complex assembly.

Similar to the situation in photoreceptors, we observe that knockout of PhLP1 in striatal neurons results in marked down-regulation in the expression of all subunits of heterotrimeric G~olf~ complex. Direct side-by-side comparison of the impact on protein expression produced by elimination of individual subunits of the G~olf~-AC5 complex affords a unique opportunity to analyze the reciprocal relationship between complex components. Our results suggest a hierarchical relationship in the assembly of the complex. The stability of Gαolf requires its association with both Gβ~2~γ~7~ and AC5, but the stability of Gβ~2~γ~7~ depends only on the association with Gαolf and not AC5. In turn, stability of AC5 is dependent on both Gβ~2~γ~7~ and Gα~olf~. Given that PhLP1 directly binds to Gbg subunits ([@bib62]; [@bib69]) and has been shown to be required for folding Gβ~2~γ~7~ in transfected cells ([@bib28]), we propose the following model for the role in PhLP1 the assembly of the G~olf~-AC5 complex. PhLP1 assists the assembly of the Gβ~2~γ~7~ complex, increasing its expression, which in turn upregulates Gα~olf~. Higher levels of Gα~olf~β~2~γ~7~ promote stabilization of the AC5 by forming pre-coupled complexes with it. Thus, PhLP1 triggers a chain of events resulting in the stabilization of the entire AC5-G~olf~ complex ensuring its high expression level and setting the stoichiometry ([Figure 7](#fig7){ref-type="fig"}).10.7554/eLife.10451.009Figure 7.Schematic illustration of PhLP1 involvement in regulating G~olf-~AC5 complex assembly and signaling.PhLP1 promotes biogenesis of Gβ2γ7 and assembly of its complex with G~olf~. The trimeric Gα~olf~β~2~γ~7~ forms stable complexes with AC5 contributing to its proteolytic stability. In addition, PhLP1 regulates cAMP production by influencing G~olf~ arrangement on AC5.**DOI:** [http://dx.doi.org/10.7554/eLife.10451.009](10.7554/eLife.10451.009)

It is interesting that PhLP1 loss in striatal neurons affected G protein complexes in a selective fashion. Studies in transfected cells indicate that PhLP1 participates in folding and stabilization of virtually all Gβγ combinations including complexes of Gβ~5~ with RGS9 and RGS7 ([@bib28]). Yet, we find that in the striatum, PhLP1 elimination has no effect on the expression of many G protein subunits, including Gβ~1~, a subunit clearly impacted by PhLP1 loss in rod photoreceptors ([@bib37]). We propose that this apparent selectivity may be explained by higher susceptibility of G proteins with high expression levels to the destabilizing effects associated with PhLP1 loss than those expressed at moderate to low levels. In this scenario, PhLP1 action may be the rate-limiting factor required for achieving high expression of G proteins with abundant mRNA expression in a particular neuronal population, e.g. Gα~t1~β~1~γ~1~, Gα~t2~β~3~γ~8~ and Gαolfβ~2~γ~7~ overexpressed in rods, cones and striatal neurons, respectively. However, at this point, we also cannot rule out an alternative explanation that cellular heterogeneity in the striatum contributes to selectivity of the effects. Although *Rgs9-Cre* driver line that we used to delete PhLP1 is active in 95% of neurons in the striatum, it might have no effect on other cells such as glia that might contain a higher abundance of G protein subunits that we find to be unregulated by PhLP1.

Role of PhLP1 in regulating neurotransmitter signaling to cAMP production {#s3-3}
-------------------------------------------------------------------------

It is interesting to consider the results of this study in light of the mechanisms linking GPCR signaling in striatal neurons to cAMP production and behavior. The G~olf~ heterotrimer is known to be essential for coupling both D1 and A2A receptors in direct and indirect striatal neurons to stimulation of cAMP production ([@bib26]). Knockout of *Gnal* or *Gng7* that encode Gα~olf~ or Gγ~7~ respectively, markedly reduces the ability of D1R and A2AR agonists to increase cAMP, and this biochemical observation is paralleled by muted behavioral responses of mice to psychostimulants that activate these receptors ([@bib10]; [@bib64]; [@bib76]). Acute psychomotor responses to drugs appear to be particularly sensitive to loss of G~olf~, while adaptive behaviors to repeated drug exposure are preserved ([@bib11]; [@bib65]). Interestingly, levels of G~olf~ complex dictate particular signaling outcomes upon receptor stimulation. For example, while Gα~olf~ is critical for the ability of D1R to stimulate both cAMP production and ERK phosphorylation, Gα~olf~ haploinsufficiency leads to selective deficits in cAMP signaling without detrimentally affecting coupling to ERK ([@bib11]). This signaling dichotomy becomes even more pronounced at the level of AC5. Although, activation of either D1R and A2A clearly results in the increase in cAMP levels ([@bib10]; [@bib29]; [@bib40]) and AC5 mediates nearly 80% of this effect ([@bib40]), elimination of AC5 in mice does not diminish behavioral responses of mice to the administration of A1R and D1R agonists ([@bib29]; [@bib40]). At the same time, mice lacking AC5 have abolished responses to D2 antagonists, suggesting greater impact of signaling via AC5 in indirect pathway neurons ([@bib40]). Balance of neurotransmitter signaling between direct and indirect pathway striatal neurons is thought to set a tightly orchestrated coordination of movements ([@bib24]; [@bib49]). In agreement with this idea, mice lacking AC5 or Gγ~7~ show profound deficits in motor learning and coordination ([@bib29]; [@bib32]; [@bib60]). Furthermore, mutations in genes encoding AC5 and Gα~olf~ in humans cause dystonia, a disorder characterized by involuntary movements ([@bib7]; [@bib16]; [@bib36]). Thus, it is likely that G~olf~-AC5 axis is involved in more subtle coordination of signaling in striatal neurons that sometimes might not be evident from measuring gross motor responses to pharmacological treatment with receptor ligands.

Our findings with a mouse model lacking PhLP1 in the striatum agree well with the expectations based on the analysis of mice with disruptions in AC5 and G~olf~ components and also provide additional insight that helps further clarify integration of neurotransmitter signaling in the striatum. Our *Pdcl* cKO model displays complete lack of motor learning, deficits in psychostimulatory effects of A2AR antagonism and diminished neuroleptic responses to D2R antagonism. As with studies on *Adcy5-/-* mice ([@bib26]; [@bib40]), perhaps the most surprising result of our studies is the intact responses of mice lacking PhLP1 to D1R agonism. This observation is particularly striking given the profound down-regulation of AC5, Gα~olf~ and Gβ~2~γ~7~ in these mice paralleled by equal deficits in coupling of both D1R and A2AR to cAMP production. We think that this selectivity is likely related to downregulation of all signaling components rather than their complete loss. It is possible that striatonigral and striatopallidal neurons have differential sensitivity to changes in the efficiency of the G~olf~-AC5 coupling, creating signaling imbalance when the expression of signaling components is diminished. This effect could be either exacerbated or compensated by the loss of RGS9-2 that also controls AC5 activity ([@bib75]) and signaling downstream from D2 receptors ([@bib6]; [@bib8]; [@bib57]), further contributing to signaling imbalance. Alternatively, preservation of D1R mediated behavioral responses in *Pdcl* cKO mice may also indicate that signaling pathways other than cAMP initiated by D1 receptors ([@bib52]) play compensatory role. In any event, our study demonstrates the importance of proper Golf-AC5 complex expression and assembly for the balance of the neurotransmitter signaling in striatal neurons and introduces PhLP1 as a critical regulator of the process and an interesting molecular player to consider in the pathology of dystonia and possibly other movement disorders.

Materials and methods {#s4}
=====================

Mice and DNA constructs {#s4-1}
-----------------------

*Pdcl ^flx/flx^*mice ([@bib37]) were crossed with *Rgs9-Cre* mice ([@bib12]) to generate striatal specific PhLP1 conditional knockout (*Pdcl* cKO) mice. *Pdcl^flx/flx^* Cre(-) control littermates derived from heterozygous breeding pairs were used for all experiments. Mice were housed in groups on a 12 hr light--dark cycle with food and water available *ad libitum*. Males and females (2--5 months) were used for all experiments. All procedures were approved by the Institutional Animal Care and Use Committee (IACUC) at The Scripps Research Institute. Generation and characterization of *Gnal^+/-^* ([@bib3]), *Gng7^-/-^* ([@bib60])) and *Adcy5^-/-^* ([@bib40]) mice have been described previously.

Full length of PhLP1 and N-terminal (1--75 a.a.) truncation of PhLP1 (ΔNT-PhLP1) were cloned into pcDNA3.1 vector as previously ([@bib44]). Venus155-239-Gβ~2~ and Venus1-155-Gγ~7~ constructs were generated by replacing Gβ~1~ in Venus155-239-Gβ~1~ construct with Gβ~2~ and Gγ~2~ in Venus1-155-Gγ~2~ construct with Gγ~7~ ([@bib27]). Construction of masGRK3ct-Nluc ([@bib56]) and Flag tagged AC5 ([@bib75]) was reported previously. Gα~olf~ and D1R cDNAs were purchased from Missouri S&T cDNA Resource Center. Flag-tagged Ric-8B in pcDNA3.1 ([@bib71]) were gifts from Dr. Bettina Malnic.

Antibodies, cell-lines, immunoprecipitation and immunoblotting {#s4-2}
--------------------------------------------------------------

Hybridoma cell lines expressing mouse monoclonal AC5 antibody against human AC5 peptide CGNQVSKEMKRMGFEDPKDKN were commercially generated by Genscript. Hybridomas were cultured in DMEM/F-12 supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. Synthetic peptide (CGNQVSKEMKRMGFEDPKDKN) was covalently immobilized to beaded agarose using SulfoLink Immobilization Kit (Pierce Biotechnology). Antibodies were purified from collected hybridoma culturing medium by affinity chromatography using immobilized antigen peptide. Other antibodies used were against: c-myc (Genescript), Gβ~1~ ([@bib41]) and Gα~olf~ ([@bib10]). PhLP1 ([@bib37]); β-actin (AC-15) (Sigma-Aldrich, St. Louis, MO); Gβ~2~, Gα~q~, Gγ~7~ and Gα~o~ (K-20) (Santa Cruz Biotechnology, Dallas, TX); Gα~i1/2~ (Affinity BioReagents, Golden, CO); GFP (clones 7.1 and 13.1; Roche Applied Science); Gβ~5~ and RGS7 and RGS9-2 ([@bib46]).

For immunoblot analysis or immunoprecipitation, striatal tissue (\~15 mg) or transfected HEK293T/17 cells were homogenized by sonication in lysis buffer (1xPBS, 150 mM NaCl, 0.5% dodecyl nonaoxyethylene ether (C12E9) containing complete protease inhibitor cocktail (Roche) and phosphatase inhibitor cocktail 1 and 2 (Sigma). The homogenate was centrifuged at 16,000×g for 15 min. For immunoprecipitation, the supernatant was incubated with 3 μg of antibody as indicated and 10 μL of protein G beads for 1 hr at 4°C. Beads were washed 3 times with lysis buffer. Protein sample was eluted in SDS sample buffer containing 4M urea, incubated at 42°C for 15 min, resolved by SDS-PAGE, transferred onto PVDF membrane and subjected to immunoblot analysis.

All experiments involving cultured cells were performed in HEK293/17 cell line obtained from ATCC (Manassas, VA). The company certifies authenticity of the cell line, and guarantees it to be free of contaminants and pathogens. The cells were maintained in standard DMEM medium, and frozen in aliquots from the stock received from the ATCC. The cells were grown for no more than 20 passages. The laboratory has tested tissue culture facility and found it to be free of mycoplasma contamination.

Recombinant proteins and membrane preparations {#s4-3}
----------------------------------------------

Recombinant Gαs were expressed in BL21 (DE3) *E. coli* strain and purified by affinity chromatography on HisTALON column (Clontech, Mountain View, CA) as described previously ([@bib39]). Gαs was activated by incubation with 20 μM GTPγS in the assay buffer containing 20 mM Tris-HCl pH 7.8, 10 mM MgCl~2~, 1 mM EDTA, 1 mM dithiothreitol for 30 min at 30°C. The unbound GTPγS was then removed by Zeba spin desalting column (Life Technologies, Carlsbad, CA). His-tagged full-length PhLP1 as well as the N-terminal (1--75 a.a.) truncation of PhLP1 were purified from *E. coli* as previously described ([@bib61]). The purity of the recombinant proteins was assessed by Coomassie staining following gel separation and was found to be at least 80%.

For membrane preparation, striatal tissues were homogenized in buffer containing 250 mM sucrose, 20 mM Hepes pH 8.0, 1 mM EDTA, 2 mM MgCl~2~, 1 mM DTT and proteinase inhibitors. The homogenate was centrifuged at 2000 g to remove nuclei, followed by centrifugation at 25,000 rpm in Beckman SW28.1 rotor for 35 min in 23/43% sucrose gradient to isolate the membrane fraction. The plasma membranes were carefully collected from the layer at the 23/43% sucrose interface. The protein concentrations in plasma membrane preparations were then determined by Pierce 660nm Protein Assay Reagent (Thermo Fisher Scientific, Waltham, MA).

cAMP measurement and adenylyl cyclase activity assay {#s4-4}
----------------------------------------------------

Striatal tissues were homogenized in 0.1 N HCl (20 μL per mg tissue). Lysates were centrifuged at 600 g for 10 min. Supernatants were collected, diluted 50-fold and cAMP concentrations were quantified using a cAMP enzyme immunoassay kit (cAMP Direct EIA) following the acetylated version protocol (Enzo Life Sciences, Farmingdale, NY). The activity of adenylyl cyclase in striatal membrane preparations (1 μg protein/reaction) was determined as described previously ([@bib75]). Briefly, 1 μg of striatal membrane was treated with vehicle (basal), or indicated stimulator for 10 min at 30ºC in adenylyl cyclase assay buffer (50 mM HEPES pH 8.0, 0.6 mM EDTA, 100 μg/mL BSA, 100 μM 3-isobutyl-1-methylxanthine (IBMX), 3 mM phosphoenolpyruvate potassium, 10 μg/mL pyruvate kinase, 5 mM MgCl~2~ and 100 μM adenosine triphosphate (ATP). Reactions were stopped by adding an equal volume of 0.2 N HCl. For dose response curves of Gα~s~-GTPγS or forskolin (FSK) stimulated adenylyl cyclase activity experiments, striatal membranes were pre-incubated with 0.5 μM purified PhLP1 for 20 min on ice and then stimulated with increasing doses of Gα~s~-GTPγS or FSK as indicated. The resulting cAMP in the sample was determined by cAMP Direct EIA kit.

mRNA quantification {#s4-5}
-------------------

Total RNA from striatal tissues was extracted and quantified as previously ([@bib53]). Briefly, striatal tissues were homogenized in TRIZOL reagent (Invitrogen, ) according to the manufacturer\'s instructions. cDNA was generated from 0.5 µg of total RNA using qScript cDNA SuperMix (Quanta Biosciences, Gaithersburg, MD) according to the manufacturer\'s instructions. To analyze the RNA expression pattern of the target genes, the 7900HT Fast Real-Time PCR System (Applied Biosystems) was used with the Taqman gene expression master kit. Three biological replicates and four technical replicates for each sample were used. 10 ng of each sample were used in each real-time PCR (TaqMan Gene Expression Assay ID probes: *Pdcl*: Mm01327170_m1; *Adcy5*: Mm00674122_m1; *Gnal*: Mm01258217_m1; *Gnb2*: Mm00515865_g1; *Gng7*: Mm00515876_m1; *Rgs9*: Mm01250425_m1; Applied Biosystems). The expression ratio of the target genes was calculated using 2^−ΔΔC^~T~ method ([@bib42])with18S ribosomal RNA (ID: Mm03928990_g1) as reference. Data are shown as mean ± S.E.M.

Bioluminescence resonance energy transfer measurements {#s4-6}
------------------------------------------------------

Agonist-dependent cellular measurements of bioluminescence resonance energy transfer (BRET) between masGRK3ct-Nluc and Venus-Gβ~2~γ~7~ were performed to visualize the action of G protein signaling in living cells as previously described with slight modification ([@bib36]). Briefly, dopamine D1 receptor, Gα~olf~, Venus156-239-Gβ~2~, Venus1-155-Gγ~7~, Flag-Ric-8B and masGRK3ct-Nluc constructs together with PhLP1 or ΔNT-PhLP1 were transfected into HEK293T/17 cells at a 1:6:1:1:1:1:1 ratio using lipofectamine LTX transfection reagent (Invitrogen). 7.5 µg total DNA was delivered per 3.5 × 10^6^ cells in a 6-cm-dish. 16--24 hr post transfection, cells were stimulated with 100 µM dopamine followed by treatment with 100 µM SCH39166. The BRET signal was determined by calculating the ratio of the light emitted by the Venus-Gβ2γ7 (535 nm) over the light emitted by the masGRK3ct-Nluc (475 nm). The average baseline value recorded prior to agonist stimulation was subtracted from BRET signal values, and the resulting difference (ΔBRET) was obtained.

Histology {#s4-7}
---------

Mice were anesthetized by Avertin (tribromoethanol) and perfused transcardially with phosphate buffered saline (PBS) and 4% paraformaldehyde (PFA). Brains were collected and postfixed in 4% PFA overnight, and stored in 30% sucrose solution for cryoprotection for 3--5 days. Brains were sectioned into 50 µm slices by a sliding microtome (SM2000R, Leica). After sectioning, sample slices were stored in PBS at 4°C or in antifreeze solution at -20°C for long-term storage.

Immunofluorescent staining was performed as described previously ([@bib20]). Primary antibodies against enkephalin and substance-P (Immunostar Inc.; 1:1,1000) were used for detecting the projection from dopamine receptor D1 or D2 medium spiny neurons. Fluorescent dye-conjugated secondary antibodies (Alexa Fluor 594, Jackson ImmunoResearch Inc.) were applied during staining. The staining was performed on two brain sections including either external globus pallidus (GPe) or substantia nigra pars reticulata (SNr). After acquiring images by using a 4X objective (CFI Plan Apo, Nikon) on Nikon Ti microscope, the Nikon NIS-Elements software was used to measure mean intensity in designated area. Then values of control and mutant groups, with backgrounds subtracted, were evaluated by Student's unpaired t-test.

For neuronal cell counting in striatum, we first performed Nissl-staining in six coronal sections with 300 µm interval. Stereo Investigator software (MicroBrightField Inc.) was employed to measure the volume of striatum and evaluate the neuronal number. The number of neurons was estimated using a fractionator sampling method described previously ([@bib2]). The analysis was performed blinded to the genotypes.

Behavioral studies {#s4-8}
------------------

Locomotor activities were evaluated in automated video tracking ANY-maze open field chambers (Stoelting, Wood Dale, IL) under illuminated conditions. Mice were habituated to the testing room for 1 hr before the test on each day. On the first day, naïve mice were placed in the novel chambers without injection, and allowed to explore the chambers for 2 hr. Horizontal activity was measured in terms of the total distance traveled or distance traveled in 10-min intervals. Thigmotaxis (wall-hugging) for each subject was determined by dividing the distance traveled in the 10-cm-wide perimeter of the chamber by the total distance traveled during the 2-hr session. For pharmacological studies, mice were injected with vehicle (10 mL/kg, i.p.), D1 receptor agonist SKF 38,393 (50 mg/kg, i.p.), or A2a receptor antagonist SCH 58,261 (3 mg/kg, i.p.), and then immediately placed in the open-field chambers. Activity was monitored for 1 hr. Dose response of the same drug treatments were done on the same mice starting from the low dose first with 2-day intervals between different doses. SKF 38,393 was dissolved in saline, and SCH 58,261 was dissolved in saline solution containing 10% DMSO and 10% Kolliphor EL (Sigma Aldrich, St. Louis, MO).

Accelerating rotarod performance was tested using a five-station rotarod treadmill (IITC Rotarod, IITC Life Science, Woodland Hills, CA). Mice were habituated in the test room for an hour before the testing. Three trials were performed per day over 3 days for a total of nine trials for each animal. After placing a mouse on the rod, it was accelerated from 8 to 22 r.p.m. in 2 min. The endurance of mice on the rotarod was measured by the time to fall to the floor of the apparatus, or to turn around one full revolution while hanging onto the drum.

Catalepsy was measured in the bar test. Briefly, one hour after haloperidol (2 mg/kg, i.p.) administration, mice forepaws were gently placed over a horizontal bar fixed at a height of 5 cm above the working surface. The length of time during which the animal retained this position until the removal of one of its forepaws was recorded with the cutoff time of 180 s.

Grip strength of mice was assessed using Grip-Strength Meter (Ugo Basile, Italy). The mouse was placed over a base plate, in front of a grasping bar. The bar was fitted to a force transducer connected to the Peak Amplifier. When pulled by the tail, the mouse instinctively grasped to the bar until the pulling force overcomes their grip strength. After the mouse lost its grip on the grasping bar, a peak preamplifier automatically stored the peak pull force (in grams) achieved by the forelimbs. Grip strength of each mouse was averaged from 5 consecutive trials.

Acoustic startle response tests were performed in acoustic apparatuses with mouse enclosures (San Diego Instruments, San Diego, CA) in sound-attenuating cubicles. The amplitude of each startle response was measured using a piezoelectric movement--sensitive platform. Acoustic stimuli and steady background noise (70 dB) were delivered through a loudspeaker. Briefly, mice were put in the mouse enclosures and acclimated for 2 min. Six trials of 40-ms 120 dB white noise bursts were then presented with a variable intertribal interval. Vmax values recorded by Acoustic Startle Program (San Diego Instruments, San Diego, CA) were averaged from six startle trials for each mouse.
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Thank you for submitting your work entitled \"Stable G protein-effector complexes in striatal neurons: mechanism of assembly and role in neurotransmitter signaling\" for peer review at *eLife*. Your submission has been favorably evaluated by a Senior editor, a Reviewing editor, and two reviewers.

The reviewers have discussed the reviews with one another and the Reviewing editor has drafted this decision to help you prepare a revised submission.

Summary:

The concept of a signaling complex in the striatum is a fascinating observation worthy of publication in *eLife*. However, there was concern about some of the data that needs to be addressed prior to publication.

Essential revisions:

1\) The co-IP expt in [Figure 1A](#fig1){ref-type="fig"} needs a specificity control. One way would be to use AC5^--/--^ mouse. The lysate lanes should be shown for both WT and KO co-IP.

2\) The BRET data need to be explained. Why is haloperidol reversing an effect through D1Rs? As it stands, these results are troubling and possibly mis-interpreted.

3\) The interpretation of data shown in [Figure 3B](#fig3){ref-type="fig"} needs to be clarified. The effect could all be explained by enzyme abundance change based on the previously known chaperone function of PhLP and not requiring complex or effects of G protein-GDP form as concluded.

4\) More detail related to these concerns can be found below.

*Reviewer \#1:*

Chaperone proteins have been found to play important roles in facilitating the formation of signaling complexes that could include receptors, G protein subunits and effectors. The present data suggest that the PhLP1 chaperone may play a central role in the assembly of AC5-G~olf~ complex and in their signaling. This is a novel finding and has potentially important clinical implications.

The most striking data came from the PhLP1 conditional KO studies. Although the evidence for the role of PhLP1 in the assembly of AC5-G~olf~ complex is indirect in these genetic data, they have convincingly demonstrated that PhLP1 deficiency leads to severely impaired G~olf~-AC5 signaling and motor skill learning but not locomotion.

While the genetic data support the significance of PhLP1 in receptor signaling in vivo, it is often expected that in vitro biochemical studies could provide direct evidence for protein-protein interactions. Here the in vitro biochemical data overall provide further support for the proposed model. However, none of the data provide direct evidence. There are no data showing direct interactions between PhLP1 and AC5 or Golf. There is no direct evidence of impaired AC5-Golf complex in PhLP1 KO either. Changes in protein expression of Golf and AC5 in PhLP1 KO provide strong, but still indirect evidence. Other mechanisms cannot be ruled out.

Non-cAMP pathways are implicated in both D1 and D2 signaling. Do any of the data suggest that? For example, the lack of change in PhLP1 KO in response to D1 drugs. However, it\'s not clear why a D1 partial agonist SKF38393 was used.

AC1 and Gs are highly expressed in the striatum during embryonic and early postnatal development. Therefore cAMP signaling may not be impaired in the PhLP1 KO during development. Does this fact bring new interpretations to the knockout phenotype (for example, morphological changes in the striatum)?

*Reviewer \#2:*

This paper claims that AC5, a highly expressed AC isoform in striatum, is in stable complex with Gβ2γ7 in vivo and this is required for stability of AC5. It also claims that AC5 stability requires stable association with α, β and γ together in complex, that PhLP1 is necessary to form this complex, and that disrupting the complex by PhLP1 knockout reduces striatal cAMP signaling and produces behavioral deficits. This leads the authors to propose a large signalosome containing all of these proteins and also RGS9, with assembly of this larger signalosome dependent on PhLP1.

The authors describe an interesting and quite extensive set of experiments showing that Golf supports AC5 protein expression, likely by increasing protein stability, and that AC5 has a converse effect on Golf abundance. They show that PhLP1 over-expression increases protein abundance in HEK2 cells. PhLP1 knockout in striatum causes the reverse, and also reduction in RGS9-2. Using this mouse they observe major cytological defects in striatum, reduced cAMP production in striatal membrane fractions, and deficits in motor behaviors.

I think that this is an interesting series of experiments that convincingly shows that PhLP1 is important to support Golf, AC5 and RGS9 protein abundance in striatum. On the more critical side, I personally like the larger signalosome idea but am not convinced of it from the data shown. As far as I can tell, all of the effects observed in the PhLP1 KO are consistent with changes in overall protein abundance from co-chaperone actions of PhLP1 in beta-gamma and beta-RGS9 complex formation. The effect on AC5 abundance might indicate that it is included in the complex but might also occur secondarily through changes in Golf subunit abundance. I also think that the signaling data seem consistent with effects of protein abundance changes rather than as evidence that signaling must occur from the larger complex. The knockout mouse is very interesting but there, also, I think that the effects might be explained in a simpler way. The behavioral deficits are interesting but quite complicated to interpret, due to the cytological defects noted.

1\) The only direct evidence for the protein complexes claimed is in the co-IP shown in [Figure 1A](#fig1){ref-type="fig"}. This lacks important controls. The simplest worry is that AC5 IgG could just be sticky compared to control IgG. Different batches of non-immune serum can vary widely in nonspecific binding. One can even get tricked by pre-immune serum from the same animal due to inflammation (acute phase effect). Here the investigators have an AC5 KO mouse. In [Figure 1](#fig1){ref-type="fig"} there should be a variant of [Figure 1A](#fig1){ref-type="fig"} co-IP with AC5^--/--^ striatum. Alternative would be to use HEK2 cells to ask, at least in that system, how much α, β and γ come down in the absence of AC5 over-expression. If I understand correctly, one would also expect non-hydrolyzable GTP analogue to partially dissociate the complex but this is not shown or discussed.

2\) [Figure 2](#fig2){ref-type="fig"} reports a BRET assay designed to detect Golf activation based on free beta-gamma binding to a NanoLuc-labeled GRK2. 10 μM dopamine caused a BRET change that was reversed by 100 μM haloperidol. However, haloperidol is a D2 and not D1 antagonist, and D1 but not D2 receptors couple to Golf. Of course 100 μM is a huge concentration of haloperidol, but so is 10 μM of dopamine. Based on simple competition, I don\'t think a 10-fold excess of haloperidol will displace dopamine at D1 receptors. This makes think that the BRET results are spurious and incorrectly interpreted.

3\) The increased basal AC activity described in [Figure 3B](#fig3){ref-type="fig"} is proposed to represent enzyme activation by free α-GDP subunits due to PhLP1 over-expression. I don\'t understand this logic because AC5 protein levels are increased. Isn\'t a simpler explanation that the basal activity is increased due to more AC5 protein as shown in [Figure 3A](#fig3){ref-type="fig"}? I also don\'t see how results shown in [Figure 3G](#fig3){ref-type="fig"} control for the observed change in forskolin potency because one would not expect a difference with activated G protein instead of forskolin -- here there is not synergy but, if anything, competition that might produce an opposite effect.

10.7554/eLife.10451.011

Author response

Essential revisions:

*1) The co-IP expt in [Figure 1A](#fig1){ref-type="fig"} needs a specificity control. One way would be to use AC5^--/--^mouse. The lysate lanes should be shown for both WT and KO co-IP.*

We performed the control experiment showing the results of AC5 immunoprecipitation from AC5 knockout samples. As expected, we see no Golf pull-down from knockout lysates confirming the specificity of the AC5-G~olf~co-immunoprecipitation. These results are reported in the revised [Figure 1C](#fig1){ref-type="fig"}.

*2) The BRET data need to be explained. Why is haloperidol reversing an effect through D1Rs? As it stands, these results are troubling and possibly mis-interpreted.*

In our system we use antagonist solely to demonstrate reversibility of the signal, which serves to indicate that the effect of dopamine is mediated by the signaling initiated by the D1R. All of our conclusions are derived from analyzing the maximal responses to agonist (dopamine) application. Although classically defined as D2 antagonist, haloperidol has a reasonable affinity for D1R as well, 63 nM (JBC, 1986, 8397). We performed additional experiments, demonstrating that the BRET signal is specifically associated with the activity of the D1R and exogenous Golf and showed the equivalence of haloperidol to a more selective D1R antagonist SCH39166 in the assays. These experiments are presented in revised [Figure 2](#fig2){ref-type="fig"}.

*3) The interpretation of data shown in [Figure 3B](#fig3){ref-type="fig"} needs to be clarified. The effect could all be explained by enzyme abundance change based on the previously known chaperone function of PhLP and not requiring complex or effects of G protein-GDP form as concluded.*

We are glad that the reviewers brought up this point, which we agree was not sufficiently discussed. Based on accumulated data, we think PhLP1 affects AC5 activity by a dual mechanism. On the one hand, it upregulates AC5 activity and this effect is likely responsible for the corresponding increase in receptor stimulated cAMP production (compare \~1.7 fold expression upregulation in [Figure 3A](#fig3){ref-type="fig"} to \~ 1.5 fold of ISO driven cAMP production in [Figure 3B](#fig3){ref-type="fig"}). However, the changes in basal or FSK-induced cAMP production (\~4-fold) are much greater than the change in the AC5 expression level. This suggests the involvement of other mechanisms by which PhLP1 could regulate AC5 activity. Indeed in panels [Figure 3D](#fig3){ref-type="fig"} though 3G we provide evidence that exogenously added PhLP1 can also stimulate AC5 by releasing Gαolf from the inhibitory constraints of Gβγ. We clarified these points in the revised version of the manuscript.

Reviewer \#1:

*While the genetic data support the significance of PhLP1 in receptor signaling in vivo, it is often expected that in vitro biochemical studies could provide direct evidence for protein-protein interactions. Here the in vitro biochemical data overall provide further support for the proposed model. However, none of the data provide direct evidence. There are no data showing direct interactions between PhLP1 and AC5 or Golf. There is no direct evidence of impaired AC5-G~olf~complex in PhLP1 KO either. Changes in protein expression of Golf and AC5 in PhLP1 KO provide strong, but still indirect evidence. Other mechanisms cannot be ruled out.*

We appreciate reviewer's understanding that this report is the first to demonstrate the involvement of PhLP1 in controlling assembly of G protein signaling complexes in the striatum. Establishing the role, this study covers a wide territory from behavioral analysis of mouse behavior to alterations in signaling reactions and biochemical studies of protein complexes. When building the model describing PhLP1 involvement, we rely on previous biochemical studies that established and extensively characterized direct interactions of PHLP1 with Gβγ subunits (PNAS, 2015, 2413; JBC, 2009, 16386; Biochemistry, 1998, 15758). We understand that further studies will likely be needed to examine whether in addition to Gβγ binding, PhLP1 also forms direct interactions with AC5 or Gαolf. Thus, our scheme summarizing the conclusions from this work ([Figure 7](#fig7){ref-type="fig"}) is tempered and reflects only what we established beyond reasonable doubt (indirect effects through Gβγ).

*Non-cAMP pathways are implicated in both D1 and D2 signaling. Do any of the data suggest that? For example, the lack of change in PhLP1 KO in response to D1 drugs. However, it\'s not clear why a D1 partial agonist SKF38393 was used.*

The reviewer is absolutely correct; we did not consider that non-cAMP pathways initiated by the D1R may compensate for the down-regulation of G~olf~-AC5 signaling branch. We discuss this possibility in the revised manuscript. The choice of SKF38393 was dictated by its selectivity for D1 receptor and extensive use in hundreds of similar studies, creating a convenient reference for the expected effects or the lack of thereof.

*AC1 and Gs are highly expressed in the striatum during embryonic and early postnatal development. Therefore cAMP signaling may not be impaired in the PhLP1 KO during development. Does this fact bring new interpretations to the knockout phenotype (for example, morphological changes in the striatum)?*

The Cre driver line that we used to knockout PhLP1 in the striatum (*Rgs9-Cre*) turns on the expression rather late in development, \~ P6 (J Neurosci, 2007, 27:14117). This coincides with the induction of Golf expression and maturation of medium spiny neurons. Thus, we think that morphological changes in the striatum that we observe are related to changes in G~olf~-AC5 signaling. However, mechanisms of morphological changes in striatal neurons were not an emphasis of this report, hence we rather focused on signaling changes in adult brains. However, we agree that examining developmental mechanisms might be an important question to be addressed in future studies.

Reviewer \#2:

*1) The only direct evidence for the protein complexes claimed is in the co-IP shown in [Figure 1A](#fig1){ref-type="fig"}. This lacks important controls. The simplest worry is that AC5 IgG could just be sticky compared to control IgG. Different batches of non-immune serum can vary widely in nonspecific binding. One can even get tricked by pre-immune serum from the same animal due to inflammation (acute phase effect). Here the investigators have an AC5 KO mouse. In [Figure 1](#fig1){ref-type="fig"} there should be a variant of [Figure 1A](#fig1){ref-type="fig"} co-IP with AC5^--/--^striatum. Alternative would be to use HEK2 cells to ask, at least in that system, how much α, β and γ come down in the absence of AC5 over-expression. If I understand correctly, one would also expect non-hydrolyzable GTP analogue to partially dissociate the complex but this is not shown or discussed.*

As mentioned in response to "Essential Revisions" point \#1, we have conducted the control experiment involving AC5 knockout tissues and report it in revised [Figure 1](#fig1){ref-type="fig"}.

*2) [Figure 2](#fig2){ref-type="fig"} reports a BRET assay designed to detect Golf activation based on free beta-gamma binding to a NanoLuc-labeled GRK2. 10 μM dopamine caused a BRET change that was reversed by 100 μM haloperidol. However, haloperidol is a D2 and not D1 antagonist, and D1 but not D2 receptors couple to Golf. Of course 100 μM is a huge concentration of haloperidol, but so is 10 μM of dopamine. Based on simple competition, I don\'t think a 10-fold excess of haloperidol will displace dopamine at D1 receptors. This makes think that the BRET results are spurious and incorrectly interpreted.*

Please refer to our response to "Essential Revisions" point \#2 above.

*3) The increased basal AC activity described in [Figure 3B](#fig3){ref-type="fig"} is proposed to represent enzyme activation by free α-GDP subunits due to PhLP1 over-expression. I don\'t understand this logic because AC5 protein levels are increased. Isn\'t a simpler explanation that the basal activity is increased due to more AC5 protein as shown in [Figure 3A](#fig3){ref-type="fig"}? I also don\'t see how results shown in [Figure 3G](#fig3){ref-type="fig"} control for the observed change in forskolin potency because one would not expect a difference with activated G protein instead of forskolin -- here there is not synergy but, if anything, competition that might produce an opposite effect.*

As we mention in response to point \#3 of "Essential Revisions" \~1.5 fold increase in AC5 expression does not fully account for \~4 fold in AC5 activity upregulation. Panels D, E, F, G of [Figure 3](#fig3){ref-type="fig"} establish that in addition to regulation of AC5 expression, PhLP1 also independently affect its activity by releasing Gαs/olf subunits. In respect to interpretation of data shown in [Figure 3G](#fig3){ref-type="fig"}, the experiment simply shows that PhLP1 is ineffective when activated Gαs is provided in the assay, because exogenous Gαs-GTP would compete with endogenous Gαolf-GDP released by PhLP1. We clarified this point in the revised manuscript.
